NASDAQ:YMAB - Y-mAbs Therapeutics Stock Price, Forecast & News

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) posted its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.70) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.54) by $0.16. View Y-mAbs Therapeutics' Earnings History.

Y-mAbs Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 27th 2020. View Earnings Estimates for Y-mAbs Therapeutics.

5 brokerages have issued 12 month price targets for Y-mAbs Therapeutics' stock. Their forecasts range from $38.00 to $40.00. On average, they anticipate Y-mAbs Therapeutics' share price to reach $39.25 in the next year. This suggests a possible upside of 11.6% from the stock's current price. View Analyst Price Targets for Y-mAbs Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Y-mAbs Therapeutics.

News stories about YMAB stock have trended extremely negative on Monday, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Y-mAbs Therapeutics earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Y-mAbs Therapeutics.

Y-mAbs Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totalling 1,650,000 shares, an increase of 55.7% from the December 31st total of 1,060,000 shares. Based on an average daily volume of 272,800 shares, the days-to-cover ratio is presently 6.0 days. Approximately 8.3% of the shares of the company are sold short. View Y-mAbs Therapeutics' Current Options Chain.

Some companies that are related to Y-mAbs Therapeutics include Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), Evotec (EVTCY), United Therapeutics (UTHR), FibroGen (FGEN), Nektar Therapeutics (NKTR), SAGE Therapeutics (SAGE), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), Allakos (ALLK), Deciphera Pharmaceuticals (DCPH), Ultragenyx Pharmaceutical (RARE), PTC Therapeutics (PTCT) and Intercept Pharmaceuticals (ICPT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital Wireless (IDCC), Stag Industrial (STAG), Corbus Pharmaceuticals (CRBP), Evoke Pharma (EVOK), Inovio Pharmaceuticals (INO), JD.Com (JD), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Alibaba Group (BABA).

(YMAB) raised $80 million in an initial public offering on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

Y-mAbs Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Strs Ohio (0.06%). Company insiders that own Y-mAbs Therapeutics stock include Ashu Tyagi, James Healy, Johan Wedell-Wedellsborg, Moller San Pedro Claus Juan and Thomas Gad. View Institutional Ownership Trends for Y-mAbs Therapeutics.

YMAB stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include Ashu Tyagi, James Healy and Moller San Pedro Claus Juan. View Insider Buying and Selling for Y-mAbs Therapeutics.

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of YMAB stock can currently be purchased for approximately $35.16.

Y-mAbs Therapeutics has a market capitalization of $1.40 billion. The company earns $-43,270,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Y-mAbs Therapeutics employs 32 workers across the globe.View Additional Information About Y-mAbs Therapeutics.

The official website for Y-mAbs Therapeutics is http://www.ymabs.com/.

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]